Axaron Bioscience AG is a biotech company that aims to develop drugs which address the large-volume and fast growing neurodegenerative disorders market. The company has built an attractive portfolio of compounds focused on the treatment of stroke, Spinal Cord Injury (SCI), ALS (Amyotrophic Lateral Sclerosis) and Parkinson's disease. The most advanced drug candidate AX200 has already entered phase II stroke trials at the end of 2004. Another compound, AX201 is scheduled for phase II clinical trials for stroke in 2006. Based on its proprietary D FINE platform, Axaron is able to quickly identify and develop drugs with neuroprotective or neuroregenerative properties. This enables the company to generate a constant flow of new drug candidates.
| Contact Details: |
| Im Neuenheimer Feld 515 |
| Heidelberg |
| |
| 69120 |
| Germany |
| Tel: | 49 (0) 6221 454 6 |
| Fax: | 49 (0) 6221 454 700 |
| Email: | contact@axaron.com |
| WWW: | www.axaron.com/
|
| |
Recent Publications by Axaron Bioscience AG: |  |
iGentifier: indexing and large-scale profiling of unknown transcriptomes.
Development and refinement of methods to analyse differential gene... | 15th September, 2007
| Gentana GmbH, Axaron Bioscience AG, Im Neuenheimer Feld 515, D-69120
| Nucleic Acids Res. 2007;35(14):4640-8. Epub 2007 Jun 25.
DOI Direct Link |
An extended window of opportunity for G-CSF treatment in cerebral ischemia.
BACKGROUND: Granulocyte-colony stimulating factor (G-CSF) is known as a... | 9th December, 2006
| Axaron Bioscience AG, Im Neuenheimer Feld 515, 69120 Heidelberg, Germany.
| BMC Biol. 2006 Oct 18;4:36.
DOI Direct Link |
Long-term gene expression changes in the cortex following cortical ischemia revealed by transcriptional profiling.
Cerebral ischemia evokes changes in gene expression time-dependently after... | 6th September, 2006
| Department of Molecular Neurology, Axaron Bioscience AG, Im Neuenheimer
| Exp Neurol. 2006 Jul;200(1):135-52. Epub 2006 Mar 10.
DOI Direct Link |
Effects of antidepressant treatment on gene expression profile in mouse brain: cell type-specific transcription profiling using laser microdissection and microarray analysis.
A gene expression study of mice treated with the tricyclic antidepressant... | 24th May, 2006
| AXARON Bioscience AG, Heidelberg, Germany.
| J Neurochem. 2006 Apr;97 Suppl 1:44-9.
DOI Direct Link |
A role for G-CSF (granulocyte-colony stimulating factor) in the central nervous system.
G-CSF (Granulocyte-colony stimulating factor) is a hematopoietic growth... | 5th May, 2006
| Axaron Bioscience
| Cell Cycle. 2005 Dec;4(12):1753-7. Epub 2005 Dec 27.
|
→View more Axaron Bioscience AG research publications. |
Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 425 times since April 2007, the link to the organisation's website has been followed 93 times
Search for more companies in Heidelberg
Search for more companies in
This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for
Axaron Bioscience AG
